Rosa Biotech accelerates NASH pre-clinical trial in liver disease
The company, spun out from the University of Bristol in 2019, is initially targeting the early identification of non-alcoholic fatty liver disease (NAFL) which, if left untreated, can develop into steatohepatitis (NASH) leading to liver failure.
The number of global NASH cases has grown significantly over the last 30 years and this trend is expected to accelerate in the coming decades.
Rosa’s Pandra platform combines patented synthetic biology with sophisticated machine learning and is particularly suited to the detection at scale of a range of life-threatening diseases with high accuracy in patient blood samples.
The company is currently collaborating with scientists, clinicians and industry to further develop and validate Pandra and bring its first tests into the clinic.
According to Rosa Biotech, the Pandra platform is particularly relevant given the tsunami of chronic diseases expected to affect large parts of the developed world in the coming decade, and the current difficulties in cost effectively diagnosing these at scale early enough for interventions.
The £415,000 seed investment comes from a group of experienced technology and life sciences entrepreneurs, and builds upon substantial investment that has already been deployed by the business.
It will allow Rosa to accelerate pre-clinical NAFLD/NASH trials, and provides a bridge to Series A funding, planned for later this year, targeting full commercialisation of Rosa’s NAFLD/NASH offering.
The pre-clinical evaluations will use samples from The National Institute for Health and Care Research BioResource, the British government’s major funder of clinical, public health, social care and translational research, and University Hospitals of Coventry and Warwick NHS Trust.
“The prevalence of NAFLD is increasing at an alarming rate, placing an ever-growing burden on specialist healthcare resources. With over 100 therapeutic interventions in clinical development, it’s critical that healthcare providers can cost effectively screen for early signs of this condition, enabling treatment and lifestyle changes to occur early enough to prevent permanent liver damage and failure,” said Dr Mark Street-Docherty, CEO of Rosa Biotech.
“With Series A funding expected to follow later in the year, this is an incredibly exciting time for our business. Pandra technology is moving ever closer to commercialization, and will enable Rosa Biotech to save lives and help protect vital healthcare infrastructure.”
Jon Craton, Chairman of Rosa Biotech, added: “Despite the huge advances in medicine in recent decades, there remains a significant number of life-affecting diseases that remain hard to diagnose at scale. This is hampering the rollout of screening programs that could profoundly impact quality of life and life expectancy for millions of people in the Western world and in developing economies.”
“Rosa’s mission is to address this challenge for a wide range of chronic and serious diseases - the combination of our innovative platform-based technology with sophisticated AI will allow us to make that vision a reality.”
